Lexeo Therapeutics (LXEO) Assets Average (2023 - 2026)

Lexeo Therapeutics (LXEO) has 4 years of Assets Average data on file, last reported at $259.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 90.38% year-over-year to $259.5 million; the trailing twelve-month figure through Mar 2026 stood at $259.5 million (up 90.38% YoY), and the FY2025 full-year result was $207.8 million, up 44.95% from the prior year.
• Assets Average advanced to $259.5 million in Q1 2026, from $206.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $259.5 million in Q1 2026 to a low of $97.3 million in Q4 2023.
• A 4-year average of $173.3 million and a median of $168.5 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average dropped 25.53% in 2025 and surged 90.38% in 2026, its largest moves.
• Tracing LXEO's Assets Average over 4 years: stood at $97.3 million in 2023, then soared by 64.91% to $160.4 million in 2024, then rose by 28.59% to $206.3 million in 2025, then advanced by 25.82% to $259.5 million in 2026.
• Business Quant data shows LXEO's Assets Average at $259.5 million in Q1 2026, $206.3 million in Q4 2025, and $160.0 million in Q3 2025.